nach oben

Zeitschrift für Rheumatologie

Erschienen in:

30.06.2016 | Rheumatoide Arthritis | Leitthema: Meilensteine in der Rheumatologie: 75 Bände Innovation

„Treat to target“ und personalisierte Medizin („precision medicine“)

verfasst von: Dr. J. Detert, MHBA, G. R. Burmester

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Auszug

In der Behandlung der rheumatoiden Arthritis (RA) entstehen europaweit jährlich ca. 14 Billionen € direkter Kosten durch Hospitalisation, Diagnostik und Therapie und ca. 17 Billionen € indirekte Kosten durch Arbeitsausfall, Frühberentung usw. Ein RA-Patient in Deutschland ist innerhalb von 10 Jahren nicht mehr arbeitsfähig, wenn die RA durch einen instabilen und nicht ausreichenden Behandlungsverlauf gekennzeichnet ist [1]. Hinzu kommt, dass Patienten diese chronische Erkrankung durchaus 30 Jahre und länger bewältigen müssen, da die RA nicht selten in jungen Jahren beginnt. Für RA-Patienten resultieren daraus unter anderem eingeschränkte soziale Beziehungen, geringe Umsetzungsmöglichkeiten aller Zukunftspläne und eine vergleichbare schlechte Lebensqualität, die der eines Patienten mit multipler Sklerose entspricht [1]. …

Lundkvist J, Kastäng F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8(Suppl 2):S49–60. doi:10.1007/s10198-007-0088-8CrossRefPubMed

Wolfe F (1996) The natural history of rheumatoid arthritis. J Rheumatol Suppl 44:13–22PubMed

Wolfe F, Hawley DJ (1998) The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 25(11):2108–2117PubMed

Sokka T, Kautiainen H, Möttönen T et al (1999) Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 26(8):1681–1685PubMed

Goldbach-Mansky R, Mahadevan V, Yao L et al (2003) The evaluation of bone damage in rheumatoid arthritis with magnetic resonance imaging. Clin Exp Rheumatol 21(5 Suppl 31):S50–3PubMed

Smolen JS, Emery P, Fleischmann R et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383(9914):321–332. doi:10.1016/S0140-6736(13)61751-1CrossRefPubMed

Hetland ML, Lindegaard HM, Hansen A et al (2008) Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 67(7):1023–1026. doi:10.1136/ard.2007.087262CrossRefPubMed

Hetland ML, Jensen DV, Krogh NS (2014) Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. Clin Exp Rheumatol 32(5 Suppl 85):S141–S146

Huscher D, Mittendorf T, Hinüber U von et al (2015) Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis 74(4):738–745. doi:10.1136/annrheumdis-2013-204311CrossRefPubMed

10.

Haschka J, Englbrecht M, Hueber AJ et al (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75(1):45–51. doi:10.1136/annrheumdis-2014-206439CrossRefPubMed

11.

Pincus T, O’Dell JR, Kremer JM (1999) Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 131(10):768–774CrossRefPubMed

12.

Kooij SM van der, Le Cessie S, Goekoop-Ruiterman YPM et al (2009) Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 68(7):1153–1158. doi:10.1136/ard.2008.093294CrossRefPubMed

13.

Abasolo L, Ivorra-Cortes J, Leon L et al (2015) Influence of demographic and clinical factors on the mortality rate of a rheumatoid arthritis cohort: A 20-year survival study. Semin Arthritis Rheum doi:10.1016/j.semarthrit.2015.10.016

14.

Schneider M, Abholz H, Caratti R et al (2007) Interdisziplinäre Leitlinie Management der frühen rheumatoiden Arthritis, 2. überarbeitete Auflage. Aufl. Steinkopff Verlag Darmstadt, Darmstadt

15.

Ziegler S, Huscher D, Karberg K et al (2010) Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 69(10):1803–1808. doi:10.1136/ard.2009.122101CrossRefPubMed

16.

Albrecht K, Callhoff J, Edelmann E et al (2015) Klinische Remission bei rheumatoider Arthritis. Daten aus der Früharthritiskohortenstudie CAPEA (Clinical remission in rheumatoid arthritis : Data from the early arthritis cohort study CAPEA). Z Rheumatol doi:10.1007/s00393-015-0019-5

17.

Combe B, Logeart I, Belkacemi MC et al (2015) Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 74(4):724–729. doi:10.1136/annrheumdis-2013-204178CrossRefPubMed

18.

Heimans L, Akdemir G, Wevers-de Boer KVC et al (2016) Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Res Ther 18(1):23 doi:10.1186/s13075-015-0912-yCrossRefPubMedPubMedCentral

19.

The Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. doi:10.1056/NEJM199309303291401CrossRef

20.

Fullerton B, Pöhlmann B, Krohn R et al (2016) The comparison of matching methods using different measures of balance: benefits and risks exemplified within a study to evaluate the effects of german disease management programs on long-term outcomes of patients with type 2 diabetes. Health Serv Res doi:10.1111/1475-6773.12452PubMed

21.

Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269. doi:10.1016/S0140-6736(04)16676-2CrossRefPubMed

22.

Emery P, Kavanaugh A, Bao Y et al (2015) Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis 74(12):2165–2174. doi:10.1136/annrheumdis-2014-205302CrossRefPubMed

23.

Gul HL, Ferreira JF, Emery P (2015) Remission in rheumatoid arthritis: is it all the same? Expert Rev Clin Pharmacol 8(5):575–586. doi:10.1586/17512433.2015.1061429CrossRefPubMed

24.

Sheehy C, Evans V, Hasthorpe H et al (2014) Revising DAS28 scores for remission in rheumatoid arthritis. Clin Rheumatol 33(2):269–272. doi:10.1007/s10067-013-2468-zCrossRefPubMed

25.

Pincus T, Castrejón I (2015) Are patient self-report questionnaires as “scientific” as biomarkers in “treat-to-target” and prognosis in rheumatoid arthritis? Curr Pharm Des 21(2):241–256CrossRefPubMed

26.

Smolen JS, Breedveld FC, Burmester GR et al (2015) Treating rheumatoid arthritis to target. 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15. doi:10.1136/annrheumdis-2015-207524CrossRefPubMedPubMedCentral

27.

Knowles SE, Chew-Graham C, Adeyemi I et al (2015) Managing depression in people with multimorbidity. A qualitative evaluation of an integrated collaborative care model. BMC Fam Pract 16(1):32 doi:10.1186/s12875-015-0246-5CrossRefPubMedPubMedCentral

28.

Gromnica-Ihle E, Rink M (2011) „Treat-to-Target“ aus Sicht der Betroffenen. Z Rheumatol 70(8):678–684. doi:10.1007/s00393-011-0773-yCrossRefPubMed

29.

Solomon DH, Bitton A, Fraenkel L et al (2014) Roles of nurse practitioners and physician assistants in rheumatology practices in the US. Arthritis Care Res 66(7):1108–1113. doi:10.1002/acr.22255CrossRef

30.

Kalden JR, Burkhardt H, Buß B et al (2011) Strategien zur verbesserten Versorgung von Menschen mit der Volkskrankheit „Rheuma“ am Beispiel der rheumatoiden Arthritis. Z Rheumatol 70(8):641–650. doi:10.1007/s00393-011-0763-0CrossRefPubMed

31.

Gesetz zur Verbesserung der Rechte von Patientinnen und Patienten vom 20. Februar 2013. In: Bundesgesetzblatt (BGBl). Bundesanzeiger Verlag, 25. Februar 2013, S 277

32.

Evans DA, Manley KA, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2(5197):485–491

33.

Cascorbi I, Brockmöller J, Mrozikiewicz PM, Müller A, Roots I (1999) Arylamine N-acetyltransferase activity in man. Drug Metab Rev 31(2):489–502. doi:10.1081/DMR-100101932

34.

Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sörgel F, Fuhr U (2005) Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49(5):1733–1738. doi:10.1128/AAC.49.5.1733–1738.2005

35.

Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS (2007) The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 63(7):633–639CrossRef

36.

Schleidgen S, Marckmann G (2013) Old wine in new bottles? Ethical implications of individualized medicine. Ethik Med 25(3):223–231CrossRef

37.

Schleidgen S, Marckmann G (2014) Kriterien für eine ethisch angemessene Priorisierung individualisierter Therapiemaßnahmen. Gesundheitswesen 76(11):e57–e64. doi:10.1055/s-0034-1390000CrossRefPubMed

38.

Rogowski WH, Schleidgen S (2015) Using needs-based frameworks for evaluating new technologies. An application to genetic tests. Health Policy 119(2):147–155. doi:10.1016/j.healthpol.2014.11.006CrossRefPubMed

39.

Lander ES, Linton LM, Birren B, Nusbaum C et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921CrossRefPubMed

40.

Nefiodow LA, Nefiodow S (2014) Der sechste Kondratieff. Die neue lange Welle der Weltwirtschaft; die langen Wellen der weltwirtschaftlichen Entwicklung, 7., aktualisierte Aufl. Aufl. Rhein-Sieg-Verl., Sankt Augustin

41.

Garrod AE. The Lancet (1975) The incidence of alkaptonuria: a study in chemical individuality. Nutr Rev 33(3):81–83

42.

Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52(1–3):65–77

43.

Center for Drug Evaluation and Research Genomics – Table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Zugegriffen: 14 Apr 2016

44.

Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32(10):903–907

45.

MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43(1):30–37

46.

Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145):661–678

47.

Eyre S, Bowes J, Diogo D et al (2012) High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44(12):1336–1340. doi:10.1038/ng.2462CrossRefPubMedPubMedCentral

48.

Orozco G, Hinks A, Eyre S et al (2009) Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet 18(14):2693–2699. doi:10.1093/hmg/ddp193CrossRefPubMedPubMedCentral

49.

Okada Y (2014) From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis. Clin Genet 86(5):432–440. doi:10.1111/cge.12465CrossRefPubMed

50.

Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A et al (2007) TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide study. N Engl J Med 357(12):1199–1209

51.

Martínez A, Varadé J, Márquez A et al (2008) Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum 58(9):2598–2602. doi:10.1002/art.23792CrossRefPubMed

52.

Raychaudhuri S, Remmers EF, Lee AT et al (2008) Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 40(10):1216–1223. doi:10.1038/ng.233CrossRefPubMedPubMedCentral

53.

Barton A, Eyre S, Ke X et al (2009) Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum Mol Genet 18(13):2518–2522. doi:10.1093/hmg/ddp177CrossRefPubMedPubMedCentral

54.

55.

Cobb JE, Plant D, Flynn E et al (2013) Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeans. PLOS ONE 8(6):e66456 doi:10.1371/journal.pone.0066456CrossRefPubMedPubMedCentral

56.

Cortes A, Brown MA (2010) Promise and pitfalls of the Immunochip. Arthritis Res Ther 13(1):101 doi:10.1186/ar3204CrossRef

57.

Knevel R, Krabben A, Brouwer E et al (2012) Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis. A multicohort study. Ann Rheum Dis 71(10):1651–1657. doi:10.1136/annrheumdis-2011-200724CrossRefPubMed

58.

Krabben A, Knevel R, Huizinga TWJ et al (2013) Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis. J Rheumatol 40(8):1303–1306. doi:10.3899/jrheum.121392CrossRefPubMed

59.

Knevel R, Rooy DPC de, Zhernakova A et al (2013) Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 65(7):1684–1693. doi:10.1002/art.37938CrossRefPubMed

60.

Knevel R, Krabben A, Wilson AG et al (2013) A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 65(3):582–589. doi:10.1002/art.37808CrossRefPubMed

61.

Rooy DPC de, Yeremenko NG, Wilson AG et al (2013) Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 72(5):769–775. doi:10.1136/annrheumdis-2012-202184CrossRefPubMed

62.

Knevel R, Klein K, Somers K et al (2014) Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 73(11):2038–2046. doi:10.1136/annrheumdis-2013-204050CrossRefPubMed

63.

Knevel R, Rooy DPC de, Saxne T et al (2014) A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res Ther 16(3):R108 doi:10.1186/ar4558CrossRefPubMedPubMedCentral

64.

Rodriguez-Rodriguez L, Ivorra-Cortes J, Carmona FD et al (2015) PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients. A genetic study of six cohorts. Arthritis Res Ther 17(1):137 doi:10.1186/s13075-015-0830-zCrossRef

65.

Steenbergen HW van, Rodríguez-Rodríguez L, Berglin E et al (2015) A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Res Ther 17(1):1 doi:10.1186/s13075-014-0514-0CrossRefPubMedPubMedCentral

66.

Visser K, Goekoop-Ruiterman YPM, Vries-Bouwstra JK de et al (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies. Post hoc analyses from the BeSt study. Ann Rheum Dis 69(7):1333–1337. doi:10.1136/ard.2009.121160CrossRefPubMed

67.

van der Helm-van Mil AH, Huizinga TW (2008) Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 10(2):205. doi:10.1186/ar2384

68.

Daha NA, Toes REM (2011) Rheumatoid arthritis. Are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol 7(4):202–203. doi:10.1038/nrrheum.2011.28CrossRefPubMed

69.

Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38–46

70.

Pratesi F, Petit Teixeira E, Sidney J et al (2013) HLA shared epitope and ACPA. Just a marker or an active player? Autoimmun Rev 12(12):1182–1187. doi:10.1016/j.autrev.2013.08.002CrossRefPubMed

71.

Padyukov L, Seielstad M, Ong RTH et al (2011) A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70(2):259–265. doi:10.1136/ard.2009.126821CrossRefPubMed

72.

Laki J, Lundström E, Snir O et al (2012) Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis. Arthritis Rheum 64(7):2078–2084. doi:10.1002/art.34421CrossRefPubMed

73.

Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, Barton A (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 56(9):2929–2935

74.

Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(9664):659–672. doi:10.1016/S0140-6736(09)60008-8CrossRefPubMed

75.

Potter C, Gibbons LJ, Bowes JD et al (2010) Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet Genomics 20(5):338–341. doi:10.1097/FPC.0b013e32833878d7CrossRefPubMed

76.

Viatte S, Plant D, Bowes J et al (2012) Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis 71(12):1984–1990. doi:10.1136/annrheumdis-2011-201225CrossRefPubMedPubMedCentral

77.

Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, Silman AJ (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40(11):1955–1961

78.

Sugiyama D, Nishimura K, Tamaki K et al (2009) Impact of smoking as a risk factor for developing rheumatoid arthritis. A meta-analysis of observational studies. Ann Rheum Dis 69(01):70–81. doi:10.1136/ard.2008.096487CrossRef

79.

Heliövaara M, Aho K, Aromaa A, Knekt P, Reunanen A (1993) Smoking and risk of rheumatoid arthritis. J Rheumatol 20(11):1830–1835

80.

Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L; EIRA study group (2003) Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 62(9):835–841

81.

Costenbader KH, Feskanich D, Mandl LA, Karlson EW (2006) Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 119(6):503.e1–503.e9

82.

Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, Frisch M (2006) Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 8(4):R133

83.

Di Giuseppe D, Orsini N, Alfredsson L et al (2013) Cigarette smoking and smoking cessation in relation to risk of rheumatoid arthritis in women. Arthritis Res Ther 15(2):R56 doi:10.1186/ar4218CrossRefPubMedPubMedCentral

84.

Di Giuseppe D, Discacciati A, Orsini N et al (2014) Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther 16(2):R61 doi:10.1186/ar4498CrossRefPubMedPubMedCentral

85.

Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH et al (2007) Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80(5):867–875

86.

Tobón GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease. Rheumatoid arthritis. J Autoimmun 35(1):10–14. doi:10.1016/j.jaut.2009.12.009CrossRefPubMed

87.

Karlson EW, Costenbader KH (2010) Epidemiology. Interpreting studies of interactions between RA risk factors. Nat Rev Rheumatol 6(2):72–73. doi:10.1038/nrrheum.2009.276CrossRefPubMed

88.

Shi J, Stadt LA van de, Levarht EWN et al (2014) Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 73(4):780–783. doi:10.1136/annrheumdis-2013-204154CrossRefPubMed

89.

Gan RW, Trouw LA, Shi J et al (2015) Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol 42(4):572–579. doi:10.3899/jrheum.140767CrossRefPubMedPubMedCentral

90.

Alessandri C, Bartosiewicz I, Pendolino M, Mancini R, Colasanti T, Pecani A et al (2015) Anti-carbamylated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients: lack of correlation with anti-cyclic citrullinated protein antibodies and rheumatoid factor. Clin Exp Rheumatol 33(6):824–830

91.

Miller WD (1891) The human mouth as a focus of infection. Dent Cosmos 33:689–713

92.

Billings F (1916) Focal infection: the lane medical lectures. Appleton and Company, New York. S 1854–1932

93.

Ogrendik M (2009) Rheumatoid arthritis is linked to oral bacteria. Etiological association. Mod Rheumatol 19(5):453–456. doi:10.1007/s10165-009-0194-9CrossRefPubMed

94.

Ogrendik M, Karagoz N (2015) Treatment of rheumatoid arthritis with roxithromycin. A randomized trial. Postgrad Med 123(5):220–227. doi:10.3810/pgm.2011.09.2478CrossRef

95.

Detert J, Pischon N, Burmester GR et al (2010) The association between rheumatoid arthritis and periodontal disease. Arthritis Res Ther 12(5):218 doi:10.1186/ar3106CrossRefPubMedPubMedCentral

96.

Konig MF, Paracha AS, Moni M et al (2015) Defining the role of porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. Ann Rheum Dis 74(11):2054–2061. doi:10.1136/annrheumdis-2014-205385CrossRefPubMed

97.

Shimada A, Kobayashi T, Ito S et al (2016) Expression of anti- porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis. J Periodont Res 51(1):103–111. doi:10.1111/jre.12288CrossRefPubMed

98.

Heap GA, Heel DA van (2009) The genetics of chronic inflammatory diseases. Hum Mol Genet 18(R1):R101–R106. doi:10.1093/hmg/ddp001CrossRefPubMed

99.

Harper AR, Topol EJ (2012) Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 30(11):1117–1124. doi:10.1038/nbt.2424CrossRefPubMed

100.

Silverman GJ, Pelzek A (2014) Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responses. J Rheumatol 41(5):825–828. doi:10.3899/jrheum.140022CrossRefPubMedPubMedCentral

101.

Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T et al (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63(10):1227–1231

102.

Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G et al (2004) Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14(11):733–739

103.

Stamp L, Roberts R, Kennedy M, Barclay M, O‘Donnell J, Chapman P (2006) The use of low dose methotrexate in rheumatoid arthritis – are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 60(10):678–687CrossRefPubMed

104.

Goodman S (2010) Measuring methotrexate polyglutamates. Clin Exp Rheumatol 28(5 Suppl 61):S24–S26

105.

Kurkó J, Besenyei T, Laki J et al (2013) Genetics of rheumatoid arthritis – A comprehensive review. Clin Rev Allergy Immunol 45(2):170–179. doi:10.1007/s12016-012-8346-7CrossRefPubMedPubMedCentral

106.

Salazar J, Moya P, Altés A et al (2014) Polymorphisms in genes involved in the mechanism of action of methotrexate. Are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics 15(8):1079–1090. doi:10.2217/pgs.14.67CrossRefPubMed

107.

Owen SA, Hider SL, Martin P et al (2012) Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 13(3):227–234. doi:10.1038/tpj.2012.7CrossRefPubMed

108.

Gurwitz D, Pirmohamed M (2010) Pharmacogenomics: The importance of accurate phenotypes. Pharmacogenomics 11(4):469–470. doi:10.2217/pgs.10.41CrossRefPubMed

109.

Crews KR, Hicks JK, Pui C et al (2012) Pharmacogenomics and individualized medicine. Translating science into practice. Clin Pharmacol Ther doi:10.1038/clpt.2012.120

110.

Sing CW, Cheung CL, Wong IC (2015) Pharmacogenomics – how close/far are we to practising individualized medicine for children? Br J Clin Pharmacol 79(3):419–428

Titel: „Treat to target“ und personalisierte Medizin („precision medicine“)
verfasst von: Dr. J. Detert, MHBA
G. R. Burmester
Publikationsdatum: 30.06.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Rheumatoide Arthritis
Biomarker
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 6/2016
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-016-0137-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Transition von der Kinder- und Jugendrheumatologie in die internistische Rheumatologie

Mitteilungen der DGRh

Standardisierte Outcomeparameter

Molekulare physikalische Medizin bei rheumatischen Krankheitsbildern

Mitteilungen der DRL